RecruitingNCT07594587
A Study of Ruxolitinib in Patients With Graft-Versus Host Disease
Post-marketing Database Study in Patients With Graft-Versus Host Disease for JAKAVI Tablets
Sponsor
Novartis Pharmaceuticals
Enrollment
395 participants
Start Date
May 11, 2026
Study Type
OBSERVATIONAL
Conditions
Summary
This study aims to evaluate the safety and effectiveness of Jakavi® (ruxolitinib) in patients with acute graft-versus host disease (GVHD) and chronic GVHD in clinical practice.
Eligibility
Min Age: 0 Years
Inclusion Criteria2
- Patients with acute and chronic GVHD
- Patients treated with ruxolitinib
Exclusion Criteria1
- None
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07594587
Related Trials
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
NCT000015291 location
Chronic Graft-versus-Host Disease in the Oral Cavity of Patients Following Allogeneic Hematopoietic Stem Cell Transplant and Including Healthy Controls
NCT036025991 location
Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD)
NCT052891671 location
A Study of Photobiomodulation (PBM) Therapy in People With Oral Graft-Versus-Host Disease (GVHD) After Stem Cell Transplant
NCT056759309 locations
Cord Blood Transplantation in Children and Young Adults With Blood Cancer
NCT075663771 location